Gravity Analytica

Pulse Biosciences To Present at the 43rd Annual J.P. Morgan Healthcare Conference

PLSE 01.03.2025

SERA-AI Powered Highlights

Date of Upcoming Event:2025-01-15

Name of Upcoming Event:43rd Annual J.P. Morgan Healthcare Conference

Full Press Release SEC Filings Our PLSE Tweets

About Gravity Analytica

Recent Filings

MIAMI--(BUSINESS WIRE)--Jan. 3, 2025--Pulse Biosciences, Inc.(Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field AblationTM (nano-PFA or nsPFATM) technology, today announced plans to present at the upcoming 43^rdAnnualJ.P. Morgan Healthcare ConferenceinSan Francisco.

Pulse Biosciences’ Management is scheduled to present onWednesday, January 15, 2025, at3:45 pm PT. A live and recorded webcast of the presentation will be available on the “Events Calendar and Presentations” page of the company’s investor website athttp://investors.pulsebiosciences.com/.

AboutPulse Biosciences®

Pulse Biosciencesis a novel bioelectric medicine company committed to health innovation that has the potential to improve the quality of life for patients. The Company’s proprietary CellFX® nsPFATM technology delivers nanosecond pulses of electrical energy to non-thermally clear cells while sparing adjacent noncellular tissue. The Company is actively pursuing the development of its CellFX nsPFA technology for use in the treatment of atrial fibrillation and in a select few other markets where it could have a profound positive impact on healthcare for both patients and providers.Pulse Biosciencesis now headquartered inMiami, Floridaand maintains its office inHayward, California.

Pulse Biosciences, CellFX, Nano-Pulse Stimulation, NPS, nsPFA, CellFX nsPFA and the stylized logos are among the trademarks and/or registered trademarks ofPulse Biosciences, Inc.inthe United Statesand other countries.

View source version onbusinesswire.com:https://www.businesswire.com/news/home/20250103001491/en/

Investors:Pulse Biosciences, Inc.Darrin Uecker, CTO orKevin Danahy,CCOIR@pulsebiosciences.com

Gilmartin GroupPhilip Trip Taylor415.937.5406philip@gilmartinir.com

Source:Pulse Biosciences, Inc.

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com